Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoCARHP: Neoadjuvant TCHP vs THP in HER2+ Breast Cancer
NCT04858529Phase 3Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab, pertuzumab in HER2-positive breast cancer, sponsored by Guangdong Provincial People's Hospital. Status: unknown.
02
Drugs
trastuzumabpertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04858529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04858529.